Sirius Fine Chemicals SiChem GmbH announces a co-operation agreement with Enamine Ltd.

Kiev, Ukraine, 24 September 2007. Sirius Fine Chemicals SiChem GmbH (sichem.de) announces a co-operation agreement with Enamine Ltd (enamine.net). Recognizing challenges of contemporary drug discovery with growing demand for optically active compounds the two companies agreed to join their efforts in synthesis of enantiomerically pure products. Enamine is an established provider of a wide array of building blocks widely used in the pharmaceutical industry. SiChem holds an expertise in enantioseparation of organic compounds in multi-gram to multi-kilogram amounts.
Owing to this co-operation the world’s life science community can supplement its research with valuable optically pure functionalized compounds. Today, Enamine’s products provide a unique opportunity of continuous lead development. Practically all building blocks which were previously available only as racemic mixtures can now be purchased in enantiomerically pure form.
Both companies complement perfectly combining a long term experience in the technique of enantioseparation of SiChem with a big capacity of chemical synthesis of Enamine. First projects include production of enantiomerically pure unnatural amino acids. Please inquire on these and other Enamine’s products at enamine@enamine.net or info@sichem.de

Sirius Fine Chemicals SiChem GmbH
Fahrenheitstrasse 1
28359 Bremen
Germany
contact person: Dr. Miriam Rittner

SiChem synthesizes fine chemicals and diagnostic tools for biochemical, biomedical, and pharmaceutical research. The core expertise is in the field of intracellular signaling, especially on derivatives of inositol phosphates and phosphoinositides. SiChem offers currently about 60 ultrapure compounds, based on its platform technology. The distribution is based on direct interaction with customers or internationally operating distributors.
SiChem’s unique expertise is based on the synthesis of masked derivatives of compounds that are usually not suitable for drug development. The masked drug candidates are successfully tested against several pathological conditions, for instance cystic fibrosis, diarrhea, and inflammation. Some products were tested positively in animal and ex-vivo patient experiments.
Custom syntheses are performed on a regular basis. SiChem offers state-of-the-art solutions for analytical problems.
We support our customers by synthesizing and separating their drug candidates.
We provide:
multi-step organic synthesis from targets and chiral building blocks
Separation of racemates,
Medicinal chemistry,
Purifying compounds (crystallization),
Compound library SiLib with a high percentage of drug candidates that have never been tested in classical or HTS assays

This release was published on openPR.